130 related articles for article (PubMed ID: 27342034)
21. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.
Andersson E; Eldfors S; Edgren H; Ellonen P; Väkevä L; Ranki A; Mustjoki S
Exp Dermatol; 2014 May; 23(5):366-8. PubMed ID: 24689486
[TBL] [Abstract][Full Text] [Related]
22. Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.
Su T; Duran GE; Kwang AC; Ramchurren N; Fling SP; Kim YH; Khodadoust MS
Oncoimmunology; 2022; 11(1):2115197. PubMed ID: 36046812
[TBL] [Abstract][Full Text] [Related]
23. Sézary Syndrome, recent biomarkers and new drugs.
Cristofoletti C; Narducci MG; Russo G
Chin Clin Oncol; 2019 Feb; 8(1):2. PubMed ID: 30525758
[TBL] [Abstract][Full Text] [Related]
24. Sézary syndrome without erythroderma.
Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
26. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
27. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.
Karenko L; Hahtola S; Päivinen S; Karhu R; Syrjä S; Kähkönen M; Nedoszytko B; Kytölä S; Zhou Y; Blazevic V; Pesonen M; Nevala H; Nupponen N; Sihto H; Krebs I; Poustka A; Roszkiewicz J; Saksela K; Peterson P; Visakorpi T; Ranki A
Cancer Res; 2005 Sep; 65(18):8101-10. PubMed ID: 16166283
[TBL] [Abstract][Full Text] [Related]
28. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
30. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.
Thompson AK; Killian JM; Weaver AL; Pittelkow MR; Davis MD
J Am Acad Dermatol; 2017 Apr; 76(4):683-688. PubMed ID: 28012574
[TBL] [Abstract][Full Text] [Related]
31. A new molecular paradigm in mycosis fungoides and Sézary syndrome.
Elenitoba-Johnson KS; Wilcox R
Semin Diagn Pathol; 2017 Jan; 34(1):15-21. PubMed ID: 28024703
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
Weng WK; Armstrong R; Arai S; Desmarais C; Hoppe R; Kim YH
Sci Transl Med; 2013 Dec; 5(214):214ra171. PubMed ID: 24307695
[TBL] [Abstract][Full Text] [Related]
33. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.
Ungewickell A; Bhaduri A; Rios E; Reuter J; Lee CS; Mah A; Zehnder A; Ohgami R; Kulkarni S; Armstrong R; Weng WK; Gratzinger D; Tavallaee M; Rook A; Snyder M; Kim Y; Khavari PA
Nat Genet; 2015 Sep; 47(9):1056-60. PubMed ID: 26258847
[TBL] [Abstract][Full Text] [Related]
34. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
36. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
Damsky WE; Choi J
Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
[TBL] [Abstract][Full Text] [Related]
37. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic tools in Sezary syndrome.
Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C
G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046
[TBL] [Abstract][Full Text] [Related]
39. The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers.
Klemke CD; Brade J; Weckesser S; Sachse MM; Booken N; Neumaier M; Goerdt S; Nebe TC
Br J Dermatol; 2008 Sep; 159(4):871-80. PubMed ID: 18652582
[TBL] [Abstract][Full Text] [Related]
40. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
